Deutsche Bank analyst Emmanuel Papadakis upgraded GSK to Buy from Hold with a price target of 1,700 GBp, up from 1,500 GBp. The shares are "too cheap if there is any semblance of sustainability" through fiscal 2027, which is probable given the company’s long acting injectables in HIV and RSV, with potential upside from bepirovirsen in hepatitis B, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
- GSK Pharma call volume above normal and directionally bullish
- GSK says MenABCWY combination vaccine candidate met all 11 primary endpoints
- GSK reports China NMPA accepts regulatory submission for Nucala
- GSK says FDA Advisory Committee supports effectiveness and safety of RSV vaccine
- GSK Pharma put volume heavy and directionally bearish
